439 results about "Autoimmunity" patented technology

Provided herein are antibodies and antibody fragments that bind to human TNFRSF25. The antibodies may be monoclonal and / or biparatopic antibodies and / or single-chain fragment variable (scFv) antibodies. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25-binding antibody.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein, such as a cytokine. In various embodiments, the disclosure also provides methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immunological disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides methods of treating aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immune disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

Provided herein are methods, devices, and systems comprising identification of a panel of gene markers useful for immune cell typing and identifying, detecting, and / or monitoring disease conditions in a subject in need thereof, including infections, cancer and autoimmune conditions. The methods also provide for assays for determining the levels of said markers prior to and after treatment of a condition in the subject, wherein the condition is impacted by one or more factors including age, occupation or environment of the subject.

The technology described herein relates to methods of inhibiting Peptidoglycan Recognition Protein 1 (Pglyrp1) in order to improve immune-checkpoint inhibitor treatments for cancer and autoimmune diseases.

Disclosed are AAV viral-based vector compositions useful in delivering a variety of nucleic acid segments, including those encoding therapeutic polypeptides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver-directed AAV-based gene therapeutic regimen for treating and / or ameliorating autoimmune disorders such as multiple sclerosis. Further disclosed are nucleic acid segments encoding therapeutic polypeptides that have been codon-optimized for expression in human cells.

The present invention relates to autoantibodies against NaV1.5 channel, their use as biomarker for the diagnosis of Brugada syndrome in human beings and relative methods of detection and therapeutic approach to target this new discovered form of autoimmunity.

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.

Described herein is a method of treating an autoimmune and / or inflammatory condition in an individual in need thereof, the method comprising (a) systemic administration of a first inhibitor to the individual in need thereof, wherein the first inhibitor comprises an inhibitor of interleukin-23 (IL-23), an inhibitor of tumor necrosis factor alpha (TNF-alpha), or combinations thereof; and (b) local administration of a second inhibitor to the individual in need thereof, wherein the second inhibitor comprises an inhibitor of interleukin-23 (IL-23), an inhibitor of tumornecrosis factor alpha (TNF-alpha), a Janus kinase (JAK) inhibitor, a sphingosine- 1 phosphate (SIP) modulator, an inhibitor of TNF-like ligand 1 A (TL1 A), or combinations thereof, thereby treating the autoimmune and / or inflammatory condition in the individual in need thereof.

The invention discloses a mouse model for treating in-situ pulmonary nodules by using bacterial lysates as well as a construction method and application of the mouse model. The method comprises the following steps: constructing an in-situ pulmonary nodule KT mouse model, instilling adenovirus, randomly dividing the model into an in-situ pulmonary nodule control group and a treatment group, performing bacterial lysate administration on mice in the treatment group at the maximum treatment dosage of 35mg / kg / d, and administering the same dosage of PBS solution to the control group. According to the invention, the possibility of killing cancer cells and preventing precancerous lesion progression by promoting autoimmunity of mice through oral immunostimulation drugs is provided for the first time, namely, the curative effect and mechanism of new drugs are researched through a mouse model, so that the clinical indications of the drugs are widened, and the blank field of clinical pulmonary nodule drug treatment is supplemented.

The invention discloses a preparation method of a stem cell exosome chitosan compound covered stent. The stem cell exosome chitosan compound comprises a stem cell exosome and a chitosan compound. In the stem cell exosome and chitosan compound, the mass percent of chitosan is 3%-10%, and the number of the stem cell exosomes is 109-1011. Compared with a traditional covered stent, the covered material provided by the invention can resist inflammation, inhibit bacteria, protect vascular endothelial cells covered by the stent, promote tissue repair, prevent tissue adhesion, prevent fibrosis and inhibit exclusion reaction and autoimmunity.

Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and / or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

Disclosed are anti-CD45 antibodies, antigen binding fragments thereof, and antibody drug conjugates (ADCs) that specifically bind to human CD45. Such antibodies and ADCs are useful in therapeutic methods, including methods of depleting CD45+ cells from a patient. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy, and to improve the engraftment of hematopoietic stem cell transplants, by selectively depleting endogenous CD45+ cells prior to the transplant procedure.

The present invention relates to a multiplex immunoassay method for diagnosing autoimmune nodopathy and, more specifically, to a multiplex immunoassay method, comprising the steps of: (1) binding CNTN1, Caspr1, NF155, and NF186 proteins each to microspheres having different color codes; (2) mixing the microspheres having different color codes to which the proteins are each bound; (3) treating the mixed microspheres with a biological sample to induce an antigen-antibody reaction; (4) adding a detection antibody; and (5) reading fluorescence information of the microspheres to measure the presence or absence of anti-CNTN1 antibody, anti-Caspr1 antibody, anti-NF155 antibody, or anti-NF186 antibody in the biological sample and quantify amounts thereof, thereby enabling simultaneous testing of four antibodies for rapid diagnosis of autoimmune nodopathy.

Provided herein are antibodies and antibody fragments that bind to human TNFRSF25. The antibodies may be monoclonal and / or biparatopic antibodies and / or single- chain fragment variable (scFv) antibodies. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25- binding antibody.

The disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts thereof) that degrade the protooncogene VAV 1 protein (VAV1). These chemical entities are useful, for example, in the treatment of subjects suffering from inflammatory or autoimmune disorders (e.g., human subjects).

The disclosure provides a method of treating or reducing the risk of developing an alloimmune condition or an autoimmune condition in a subject in need thereof. The method comprises (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic.

The invention belongs to the technical field of biological medicines, discloses a fusion protein as well as a preparation method and application thereof, and particularly discloses a fusion protein which comprises a DDX60 functional structural domain and a tumor-targeted cell-penetrating peptide. The invention provides a fusion protein, the fusion protein has tumor targeted cell penetrability and can activate anti-tumor immunity, and the fusion protein can directly send a DDX60 functional structure domain into tumor cells and maintain the stability of dsRNA; meanwhile, the protein can improve the sensitivity of other anti-tumor immunotherapies by activating the autoimmunity of a body, a new thought is provided for the development of anti-cancer targeted drugs, the efficiency and the application range of the existing anti-tumor immunotherapies are expanded, and the protein has important significance in tumor treatment.

The invention discloses an IL10-secreting and BAFFR-targeting chimeric antigen receptor, a CAR-T cell and application. The IL10-secreting and BAFFR-targeting chimeric antigen receptor comprises a signal peptide region, a BAFFR-targeting antigen binding domain, a hinge region, a transmembrane structural domain, a co-stimulation structural domain, a signal transduction structural domain and human IL10 which are sequentially connected from an amino terminal to a carboxyl terminal, wherein the signal peptide region, the BAFFR-targeting antigen binding domain, the hinge region, the transmembrane structural domain, the co-stimulation structural domain, the signal transduction structural domain and the human IL10 are sequentially connected from the amino terminal to the carboxyl terminal; the co-stimulation structural domain comprises a CD28 co-stimulation structural domain and a 4-1BB co-stimulation structural domain which are connected, and the signal transduction structural domain is ITAM1 of CD3 zeta. The kit can specifically aim at autoimmune B cells, and immunodeficiency and patient infection caused by full B cell deletion are avoided. The secretion of IL10 on the CAR-T cells can reduce the depletion rate of the CAR-T cells in vivo, so that the long-acting inhibition effect on the disease process is achieved.

The application relates to methods for the diagnosis, treatment, and prevention of autoimmune and / or inflammatory disease such as systemic lupus erythematosus (SLE) and lupus nephritis.

The invention belongs to the technical field of cell bionic nano-drugs, and particularly discloses a cell bionic nano-particle as well as a construction method and application thereof. And performing simple ultrasonic fusion on the target cell membrane and the hydrophobic nano-core to obtain the cell bionic nano-particles. The bionic nano-cell can effectively inherit and simulate functional protein on the surface of a source cell membrane, systematically replace functions of the source cell in physiological and pathological processes, such as inflammatory factor adsorption, migration factor adsorption and the like, interfere and inhibit the disease process from the cellular mechanism, regulate and control cell composition and immune microenvironment of a focus part, and improve the immune function of the source cell membrane. The medicine does not need to be additionally carried. Aiming at the related pathogenesis of immune tolerance deficiency, the invention innovatively provides a therapeutic strategy for constructing immune tolerance. The homology and inherent immunosuppressive ability of tumor cells to the focus part of the autoimmune disease are reversely used, immune tolerance of the focus part based on immune checkpoints is reconstructed, meanwhile, target cells are replaced to adsorb autoimmune antibodies, and the immune response level is reduced.

The invention belongs to the field of biological medicine, and particularly relates to a varicella-zoster virus gB protein mutant and application thereof. According to the gB protein mutant of the varicella-zoster virus, provided by the invention, proline mutation, shearing of N-terminal and C-terminal structural domains, release of electrostatic repulsive force in the protein, mutation of a Frelin enzyme cutting site and the like are carried out in a process of converting a gB protein fusion precursor into a fusion afterbody conformation, so that the gB protein mutant of the varicella-zoster virus is obtained. The conformation before fusion can be stabilized, and the expression quantity and the stability of the antigen protein are improved. As a vaccine component, the mutant has good immunogenicity, activates autoimmunity of animals and plays a role in prevention or treatment of vaccines.

Provided herein are novel drug-linker conjugates and antibody-drug conjugates of imidazoquinoline amine derivatives, which have agonistic activities towards Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, as well as pharmaceutical compositions and methods of treatment thereof for certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation allergy, asthma, infection, sepsis, cancer and immunodeficiency).

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-COV-2.

The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial ensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial compositions, and compositions comprising the same, in methods for treating or preventing gastrointestinal enteropathy or dysbiosis in canines. In particular aspects, the disclosure provides methods of treating or preventing morbidity and mortality caused by GI pathogenesis or autoimmunity.

Described herein are compounds useful in the treatment of TYK2 mediated disorders. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a nervous system disorder, or a disorder associated with transplantation.

The present invention provides methods of making immune effector cells (e.g., T cells, NK cells) that express chimeric antigen receptors (CARs), and compositions produced by such methods, and therapeutic uses thereof for the treatment of autoimmune diseases or disorders.